U.S. markets open in 4 hours 56 minutes

Catalyst Pharmaceuticals, Inc. (CPRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
13.73-0.24 (-1.72%)
At close: 04:00PM EDT
13.70 -0.03 (-0.22%)
After hours: 07:52PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close13.97
Bid0.00 x 1000
Ask0.00 x 800
Day's Range13.60 - 14.05
52 Week Range4.81 - 14.44
Avg. Volume1,691,140
Market Cap1.436B
Beta (5Y Monthly)1.44
PE Ratio (TTM)27.46
EPS (TTM)0.50
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-20% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for CPRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Catalyst Pharmaceuticals, Inc.
    Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • Zacks

    Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates

    Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update

    Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53.0 Million, a 57.7% YoY Increase Cash and Short-Term Investments at June 30, 2022 were $220.8 Million, with No Funded Debt Completed Acquisition of Ruzurgi® U.S. and Mexico Commercial Rights Advanced Plans to Diversify Portfolio and Invest in Innovative Rare Disease Opportunities Provides Guidance that Full-Year 2022 Adjusted EBITDA to be Between $100-105 Million Listing New Orange Book Patent Potentially Extends FIRDAPSE Patent Protec

  • GlobeNewswire

    Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022

    The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ETCORAL GABLES, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its second quarter 2022 financial results after market close on Tuesday, August 9, 2022. Catalyst's manage